These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 18363512)
1. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Kovesdy CP; Kalantar-Zadeh K Expert Opin Investig Drugs; 2008 Apr; 17(4):451-67. PubMed ID: 18363512 [TBL] [Abstract][Full Text] [Related]
2. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Lambers Heerspink HJ; de Zeeuw D Br J Clin Pharmacol; 2013 Oct; 76(4):536-50. PubMed ID: 23802504 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Filiopoulos V; Vlassopoulos D Inflamm Allergy Drug Targets; 2009 Dec; 8(5):369-82. PubMed ID: 20025585 [TBL] [Abstract][Full Text] [Related]
4. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. Badve SV; Palmer SC; Strippoli GFM; Roberts MA; Teixeira-Pinto A; Boudville N; Cass A; Hawley CM; Hiremath SS; Pascoe EM; Perkovic V; Whalley GA; Craig JC; Johnson DW Am J Kidney Dis; 2016 Oct; 68(4):554-563. PubMed ID: 27138469 [TBL] [Abstract][Full Text] [Related]
5. Role of oxidative stress on chronic kidney disease progression. Putri AY; Thaha M Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. Elewa U; Sanchez-Niño MD; Martin-Cleary C; Fernandez-Fernandez B; Egido J; Ortiz A Int Urol Nephrol; 2012 Dec; 44(6):1731-44. PubMed ID: 22965378 [TBL] [Abstract][Full Text] [Related]
7. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Ali S; Dave N; Virani SS; Navaneethan SD Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129 [TBL] [Abstract][Full Text] [Related]
9. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients. Piotr B; Mariusz S; Jacek R Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221 [TBL] [Abstract][Full Text] [Related]
10. Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. Garofolo M; Russo E; Miccoli R; Lucchesi D; Giusti L; Sancho-Bornez V; Daniele G; Del Prato S; Penno G J Diabetes Complications; 2018 Jun; 32(6):550-557. PubMed ID: 29705091 [TBL] [Abstract][Full Text] [Related]
15. The use of an anti-inflammatory supplement in patients with chronic kidney disease. Moreillon JJ; Bowden RG; Deike E; Griggs J; Wilson R; Shelmadine B; Cooke M; Beaujean A J Complement Integr Med; 2013 Jul; 10():. PubMed ID: 23828329 [TBL] [Abstract][Full Text] [Related]
16. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Sugrue DM; Ward T; Rai S; McEwan P; van Haalen HGM Pharmacoeconomics; 2019 Dec; 37(12):1451-1468. PubMed ID: 31571136 [TBL] [Abstract][Full Text] [Related]
17. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108 [TBL] [Abstract][Full Text] [Related]
18. Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. Lessey G; Stavropoulos K; Papademetriou V Vasc Health Risk Manag; 2019; 15():365-373. PubMed ID: 31686830 [TBL] [Abstract][Full Text] [Related]
19. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease. Goicoechea M; Quiroga B; García de Vinuesa S; Verdalles U; Reque J; Panizo N; Arroyo D; Santos A; Macías N; Luño J Ren Fail; 2012; 34(8):1002-9. PubMed ID: 22746155 [TBL] [Abstract][Full Text] [Related]
20. Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. Mukai H; Svedberg O; Lindholm B; Dai L; Heimbürger O; Barany P; Anderstam B; Stenvinkel P; Qureshi AR Nephrol Dial Transplant; 2019 Mar; 34(3):442-448. PubMed ID: 29378035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]